Stockreport

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF that sharply reduced progression risk and improved symptoms, a milestone the market is taking seriously. See our latest analysis for Immunome. That breakout Phase 3 [Read more]